Search results for "Glucose tolerance"

showing 10 items of 114 documents

Persistence of the effect of birth size on dysglycaemia and type 2 diabetes in old age: AGES-Reykjavik Study

2012

We studied the effect of birth size on glucose and insulin metabolism among old non-diabetic individuals. We also explored the combined effect of birth size and midlife body mass index (BMI) on type 2 diabetes in old age. Our study comprised 1,682 Icelanders whose birth records included anthropometrical data. The same individuals had participated in the prospective population-based Reykjavik Study, where BMI was assessed at a mean age of 47 years, and in the AGES-Reykjavik Study during 2002 to 2006, where fasting glucose, insulin and HbA₁c were measured and homeostasis model assessment for the degree of insulin resistance (HOMA-IR) calculated at a mean age of 75.5 years. Type 2 diabetes was…

Blood GlucoseMaleAgingmedicine.medical_specialtyPediatricsBirth weightPopulationIcelandType 2 diabetesWeight GainArticleBody Mass IndexInsulin resistanceDiabetes mellitusInternal medicinemedicineBirth WeightHumansInsulinsyntymäpainoProspective StudieseducationAgedAged 80 and overGlucose tolerance testeducation.field_of_studydiabetesmedicine.diagnostic_testbusiness.industryIncidenceagingGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseLow birth weightikääntyminenEndocrinologyDiabetes Mellitus Type 2Population SurveillanceDisease ProgressionFemaleInsulin ResistanceGeriatrics and Gerontologymedicine.symptombusinessBody mass indexbirth sizeFollow-Up StudiesAGE
researchProduct

Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endotheli…

2015

Endothelial dysfunction plays a key role in obesity-induced risk of cardiovascular disease. The aim of the present study was to analyze the effect of chronic peroxisome proliferator-activated receptor (PPAR)β/δ agonist GW0742 treatment on endothelial function in obese mice fed a high-fat diet (HFD).Five-week-old male mice were allocated to one of the following groups: control, control-treated (GW0742, 3 mg/kg per day, by oral gavage), HFD, HFD + GW0742, HFD + GSK0660 (1 mg/kg/day, intraperitoneal) or HFD-GW0742-GSK0660 and followed for 11 or 13 weeks. GW0742 administration to mice fed HFD prevented the gain of body weight, heart and kidney hypertrophy, and fat accumulation. The increase in …

Blood GlucoseMaleAgonistmedicine.medical_specialtyNitric Oxide Synthase Type IIIEndotheliumPhysiologymedicine.drug_classCaveolin 1Peroxisome proliferator-activated receptorThiophenesDiet High-FatGW0742MiceInsulin resistanceInternal medicineInternal MedicinemedicineAnimalsObesityPPAR deltaSulfonesEndothelial dysfunctionReceptorPPAR-betaAortachemistry.chemical_classificationInterleukin-6Tumor Necrosis Factor-alphabusiness.industryGlucose Tolerance TestPeroxisomemedicine.diseaseToll-Like Receptor 4VasodilationThiazolesEndocrinologymedicine.anatomical_structureAdipose TissuechemistryHypertensionAdiponectinEndothelium VascularInsulin ResistanceReactive Oxygen SpeciesCardiology and Cardiovascular MedicinebusinessJournal of Hypertension
researchProduct

Insulin resistance and endogenous digoxin-like factor in obese hypertensive patients with glucose intolerance

1992

Hypertensive obese subjects with glucose intolerance have hyperinsulinaemia, insulin resistance and intracellular cation imbalance resulting in increased sodium content. The aim of our study was to assess in these patients plasma levels of endogenous digoxin-like factor (EDLF), an inhibitor of the sodium-pump mechanism. We studied 14 hypertensive and 12 normotensive subjects with obesity and glucose intolerance for fasting blood glucose, and plasma insulin, C-peptide and EDLF levels: the two groups were matched for age and BMI and were studied after a 2-week wash-out period from hypotensive drugs. Compared with normotensives, hypertensive subjects had higher plasma insulin levels, a greater…

Blood GlucoseMaleDigoxinmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndogenyEndogenous digoxin-like factorEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusInternal MedicineHumansInsulinMedicineObesityImmunoreactive insulinC-Peptidebusiness.industryInsulinBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle AgedSaponinsmedicine.diseaseObesityCardenolidesEndocrinologyHyperglycemiaHypertensionFemaleInsulin ResistanceSodium-Potassium-Exchanging ATPasebusinessIntracellularActa Diabetologica
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Microregional distributions of glucose, lactate, ATP and tissue pH in experimental tumours upon local hyperthermia and/or hyperglycaemia

1993

Microregional distributions of glucose, lactate and ATP concentrations as well as tissue pH values were determined in subcutaneous rat tumours during normothermia and normoglycaemia, and upon local hyperthermia (HT) and/or hyperglycaemia (HG). Experiments were performed in order to investigate whether, and to what extent, these adjuvant therapeutic measures applied alone or in combination can modify the bioenergetic and metabolic status, parameters that are known to markedly influence the therapeutic response of tumours to heat. Local HT was performed in a saline bath (44 degrees C/2 h) and HG was induced by i.v. infusion of glucose for 2.5 h (blood glucose levels during heating: 35-40 mM).…

Blood GlucoseMaleHyperthermiaCancer Researchmedicine.medical_specialtyBioenergeticsmedicine.medical_treatmentBiologyRats Sprague-DawleyAdenosine TriphosphateInternal medicinemedicineAnimalsLactic AcidSalineAcidosisGlucose tolerance testmedicine.diagnostic_testHyperthermia InducedGeneral MedicineMetabolismHydrogen-Ion Concentrationmedicine.diseaseRatsGlucoseEndocrinologyOncologyMechanism of actionHyperglycemiaLactatesCrabtree effectSarcoma Experimentalmedicine.symptomJournal of Cancer Research and Clinical Oncology
researchProduct

Laser Doppler flux and tissue oxygenation of experimental tumours upon local hyperthermia and/or hyperglycaemia

1992

Laser Doppler fluxmetry and oxygen partial pressure (pO2) histography have been applied to investigate the acute effects of hyperthermia (HT) and/or hyperglycaemia (HG) on microcirculatory function and tissue oxygenation of subcutaneous rat tumours growing on the dorsum of the hind foot. The experiments were performed to test whether, and to what extent, the two adjunct treatment modalities applied alone or in combination can modify these therapeutically relevant parameters. Local HT was performed in a saline bath (44 degrees C) for 2 h; HG was induced by i.v. infusion of 40% glucose solution for 2.5 h (blood glucose levels: 35-40 mM during heating). Laser Doppler flux (LDF) in superficial …

Blood GlucoseMaleHyperthermiaCancer Researchmedicine.medical_specialtyRadiosensitizerPathologymedicine.medical_treatmentBiologyLaser doppler fluxOxygen ConsumptionCombined treatmentInternal medicinemedicineAnimalsSalineGlucose tolerance testmedicine.diagnostic_testLasersRats Inbred StrainsHyperthermia InducedNeoplasms ExperimentalGeneral MedicineOxygenationmedicine.diseaseRatsTissue oxygenationOncologyCardiologyFemaleJournal of Cancer Research and Clinical Oncology
researchProduct

Glucose regulation and pain in older people-The Helsinki Birth Cohort Study

2021

Aims: To assess if individuals with diabetes or prediabetes report more pain or have increased use of pain medication compared to normoglycaemic individuals. Methods: Using cross-sectional data, we studied 928 men and 1075 women from the Helsinki Birth Cohort Study in 2001-2004 at a mean age of 61.5 years. Glucose regulation was assessed with a 2-h 75 g oral glucose tolerance test, and applying World Health Organization criteria, participants were defined as having normoglycaemia, prediabetes (impaired fasting glucose or impaired glucose tolerance), newly diagnosed diabetes or previously diagnosed diabetes. Self-reported pain intensity and interference during the previous 4 weeks was estima…

Blood GlucoseMalePREDICTOREpidemiologyIMPACTEndocrinology Diabetes and MetabolismglukoosiaineenvaihduntaprediabetesDISEASECohort StudiesImpaired glucose tolerance0302 clinical medicinepain030212 general & internal medicinePrediabetesepidemiologiaPOPULATION2. Zero hungereducation.field_of_studyNutrition and DieteticsdiabetesDiabetesMiddle Aged3. Good healthPREVALENCEFemaleepidemiologyFamily Practiceikääntyneetmedicine.medical_specialtyPopulationPain030209 endocrinology & metabolismPrediabetic State03 medical and health sciencesInternal medicineDiabetes mellitusGlucose IntoleranceInternal MedicinemedicineHumansTOLERANCEeducationAgedbusiness.industryBeck Depression Inventorykipumedicine.diseaseImpaired fasting glucoseLIFEHIGH-RISKCross-Sectional StudiesGlucose3121 General medicine internal medicine and other clinical medicinekrooninen kipuBlood sugar regulationbusinessBody mass indexPrediabetesPERIPHERAL NEUROPATHY
researchProduct

Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism

2018

Background: Patients with type 2 diabetes mellitus (T2DM) have a higher incidence of cardiovascular (CV) events. The ingestion of high-glycemic index (GI) diets, specially sweetened beverage consumption, has been associated with the development of T2DM and CV disease. Objective: We investigated the effects of the intake of a sweetened beverage, obtained from natural carbohydrates containing pinitol (PEB) compared to a sucrose-enriched beverage (SEB) in the context of impaired glucose tolerance (IGT) and diabetes. Methods: The study was divided in three different phases: (1) a discovery phase where the plasma proteomic profile was investigated by 2-DE (two-dimensional electrophoresis) follow…

Blood GlucoseMaleProteomicstype 2 diabetes mellitusmedicine.medical_treatmentType 2 diabetes030204 cardiovascular system & hematologyBody Mass IndexImpaired glucose tolerance0302 clinical medicineInsulinInsulin-Like Growth Factor INutrition and DieteticsbiologyChemistryComplement C4aFabaceaeMiddle AgedHealthy Volunteerslcsh:Nutrition. Foods and food supplyNutritive SweetenersAdultmedicine.medical_specialtyAdolescentsweetenerBlood sugarlcsh:TX341-641030209 endocrinology & metabolismCarbohydrate metabolismArticleDiabetes Mellitus ExperimentalBeveragesinsulin-like growth factor03 medical and health sciencesYoung AdultInsulin resistanceDouble-Blind MethodInternal medicineDiabetes mellitusGlucose IntolerancemedicineAnimalsHumansC4A complementAgedGlycated HemoglobinPlant ExtractsInsulinOverweightmedicine.diseaseRatsRats Zuckerimpaired glucose tolerance; type 2 diabetes mellitus; sweetener; insulin-like growth factor; C4A complementDisease Models AnimalEndocrinologyimpaired glucose toleranceDiabetes Mellitus Type 2biology.proteinGLUT2InositolFood ScienceNutrients; Volume 10; Issue 3; Pages: 271
researchProduct

Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth h…

2014

Purpose: To evaluate the performance of various indexes of insulin sensitivity and secretion and to identify the most useful indicator of deterioration of glucose metabolism in a cohort of children with growth hormone (GH) deficiency (GHD) during GH treatment. Methods: In 73 GHD children (55 M, 18 F; mean age 10.5 years) at baseline and after 12 months of treatment, we evaluated a number of surrogate indexes of insulin secretion and sensitivity. In a subgroup of 11 children we also performed an euglycemic hyperinsulinemic clamp. Results: After 12 months, a significant increase in fasting glucose (p < 0.001) and HbA1c levels (p < 0.001) was documented, despite all children remained with a no…

Blood GlucoseMalemedicine.medical_specialtyAdolescentHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentChildren; Glucose metabolism; Growth hormone treatment; Insulin secretion; Insulin sensitivity; Endocrinology Diabetes and Metabolism; EndocrinologyHypopituitarismCarbohydrate metabolismHypopituitarismSettore MED/13 - EndocrinologiaEndocrinologyInsulin resistanceInsulin-Secreting CellsInternal medicinemedicineHormone replacement therapy (male-to-female)HumansInsulinGrowth hormone treatmentChildDwarfism PituitaryChildrenGlucose metabolismGlucose tolerance testmedicine.diagnostic_testHuman Growth Hormonebusiness.industryInsulin secretionInsulinGlucose Tolerance TestInsulin sensitivitymedicine.diseaseGrowth hormone treatmentTreatment OutcomeEndocrinologyChild PreschoolConcomitantFemaleInsulin Resistancebusiness
researchProduct

Cellular ionic alterations with age: relation to hypertension and diabetes.

2000

BACKGROUND: Cytosolic free calcium (Cai) and magnesium (Mgi) are vital to cellular homeostasis and function. OBJECTIVE: To evaluate cellular divalent cations in normal subjects at different ages and their relationship to ion levels in essential hypertension and diabetes. DESIGN: A cross-sectional study. SETTING: A university hospital in New York. PARTICIPANTS: A total of 103 subjects (32 older, 71.1 ± 1.2 y/o, and 71 young/middle aged subjects, 51.1 ± 2.3 y/o). INTERVENTION: Oral glucose tolerance test. MEASUREMENTS: 19F and 31P NMR spectroscopy were used to measure Cai and Mgi levels in erythrocytes from normal (>65 y/o, n = 11; 65 y/o, n = 9; 65 y/o, n = 12; <65 y/o, n = 15) subjects; the…

Blood GlucoseMalemedicine.medical_specialtyAgingErythrocytesMagnetic Resonance Spectroscopymedicine.medical_treatmentCellular homeostasisEssential hypertensionCytosolInternal medicineDiabetes mellitusmedicineHumansInsulinMagnesiumMagnesium ionAgedAged 80 and overGlucose tolerance testmedicine.diagnostic_testbusiness.industryInsulinAge FactorsGlucose Tolerance TestMiddle Agedmedicine.diseaseCausalityEndocrinologyGlycemic indexBlood pressureCross-Sectional StudiesDiabetes Mellitus Type 2Case-Control StudiesHypertensionCalciumFemaleGeriatrics and GerontologybusinessJournal of the American Geriatrics Society
researchProduct